{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"description":"The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria.\n\nThe categories for best objective response are CR, PR, stable disease (SD)\\>= 12 weeks, progressive disease (PD) or NE.","groups":[{"description":"Vandetanib (300 mg daily)","id":"OG000","title":"Vandetanib 300 mg"},{"description":"Placebo daily","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"RECIST assessments performed at screening (within 3 weeks before randomisation), then every 12 weeks. For patients with objective response of CR or PR, an additional confirmatory scan was performed ≥4 weeks following the date of first response.","title":"Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}